Published in Gynecol Oncol on June 27, 2012
Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet (2014) 8.59
Differences in cancer awareness and beliefs between Australia, Canada, Denmark, Norway, Sweden and the UK (the International Cancer Benchmarking Partnership): do they contribute to differences in cancer survival? Br J Cancer (2013) 2.52
Explaining variation in cancer survival between 11 jurisdictions in the International Cancer Benchmarking Partnership: a primary care vignette survey. BMJ Open (2015) 1.76
Is England closing the international gap in cancer survival? Br J Cancer (2015) 1.47
International variation in adherence to referral guidelines for suspected cancer: a secondary analysis of survey data. Br J Gen Pract (2016) 1.42
Stage at diagnosis and early mortality from cancer in England. Br J Cancer (2015) 1.15
Diagnosing cancer earlier: reviewing the evidence for improving cancer survival. Br J Cancer (2015) 1.14
Ovarian cancer symptom awareness and anticipated delayed presentation in a population sample. BMC Cancer (2014) 0.96
A differentiated approach to referrals from general practice to support early cancer diagnosis - the Danish three-legged strategy. Br J Cancer (2015) 0.95
Experience of symptoms indicative of gynaecological cancers in UK women. Br J Cancer (2013) 0.89
Does standardised structured reporting contribute to quality in diagnostic pathology? The importance of evidence-based datasets. Virchows Arch (2015) 0.87
A geographical cluster randomised stepped wedge study of continuing medical education and cancer diagnosis in general practice. Implement Sci (2014) 0.85
An investigation of routes to cancer diagnosis in 10 international jurisdictions, as part of the International Cancer Benchmarking Partnership: survey development and implementation. BMJ Open (2016) 0.82
Ultrasound-mediated destruction of LHRHa-targeted and paclitaxel-loaded lipid microbubbles induces proliferation inhibition and apoptosis in ovarian cancer cells. Mol Pharm (2013) 0.78
No socioeconomic inequalities in ovarian cancer survival within two randomised clinical trials. Br J Cancer (2014) 0.77
Estimating the workload associated with symptoms-based ovarian cancer screening in primary care: an audit of electronic medical records. BMC Fam Pract (2014) 0.77
Concordance of National Cancer Registration with self-reported breast, bowel and lung cancer in England and Wales: a prospective cohort study within the UK Collaborative Trial of Ovarian Cancer Screening. Br J Cancer (2013) 0.76
Ethical Hurdles in the Prioritization of Oncology Care. Appl Health Econ Health Policy (2016) 0.75
Diagnostic and referral intervals for Manitoba women with epithelial ovarian cancer - the Manitoba Ovarian Cancer Outcomes (MOCO) study group: a retrospective cross-sectional study. CMAJ Open (2017) 0.75
Infrequent Expression of the Cancer-Testis Antigen, PASD1, in Ovarian Cancer. Biomark Cancer (2015) 0.75
High-risk HPV is not associated with epithelial ovarian cancer in a Caucasian population. Infect Agent Cancer (2016) 0.75
Novel risk models for early detection and screening of ovarian cancer. Oncotarget (2016) 0.75
The potential role of infectious agents and pelvic inflammatory disease in ovarian carcinogenesis. Infect Agent Cancer (2017) 0.75
ShenLingLan Influences the Attachment and Migration of Ovarian Cancer Cells Potentially through the GSK3 Pathway. Medicines (Basel) (2017) 0.75
Repurposing itraconazole for the treatment of cancer. Oncol Lett (2017) 0.75
A conditional knockout resource for the genome-wide study of mouse gene function. Nature (2011) 9.93
Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol (2008) 7.18
Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst (2006) 6.73
Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J Natl Cancer Inst (2006) 6.41
Risk of developing colorectal cancer following a negative colonoscopy examination: evidence for a 10-year interval between colonoscopies. JAMA (2006) 6.26
UK health performance: findings of the Global Burden of Disease Study 2010. Lancet (2013) 6.11
In vivo absorption, scattering, and physiologic properties of 58 malignant breast tumors determined by broadband diffuse optical spectroscopy. J Biomed Opt (2006) 4.71
Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England. Lancet Oncol (2009) 4.44
Hybrid analysis for up-to-date long-term survival rates in cancer registries with delayed recording of incident cases. Eur J Cancer (2004) 4.16
Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA (2006) 4.09
Health seeking behaviour and health service utilization in Pakistan: challenging the policy makers. J Public Health (Oxf) (2004) 4.03
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol (2007) 3.91
Stage at diagnosis is a key explanation of differences in breast cancer survival across Europe. Int J Cancer (2003) 3.89
The European dimension for the mouse genome mutagenesis program. Nat Genet (2004) 3.84
Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst (2005) 3.64
Cancer survival in China, 2003-2005: a population-based study. Int J Cancer (2014) 3.32
Predicting response to breast cancer neoadjuvant chemotherapy using diffuse optical spectroscopy. Proc Natl Acad Sci U S A (2007) 3.27
Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol (2005) 3.26
PPM1D mutations in circulating white blood cells and the risk for ovarian cancer. J Natl Cancer Inst (2013) 3.15
Study design, exposure variables, and socioeconomic determinants of participation in Diet, Cancer and Health: a population-based prospective cohort study of 57,053 men and women in Denmark. Scand J Public Health (2007) 3.11
Thirty-day postoperative mortality after colorectal cancer surgery in England. Gut (2011) 3.07
National survey of British public's views on use of identifiable medical data by the National Cancer Registry. BMJ (2006) 2.92
Modeling smoking history: a comparison of different approaches. Am J Epidemiol (2002) 2.92
Stage at diagnosis and colorectal cancer survival in six high-income countries: a population-based study of patients diagnosed during 2000-2007. Acta Oncol (2013) 2.84
Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst (2008) 2.78
Imaging in breast cancer: diffuse optics in breast cancer: detecting tumors in pre-menopausal women and monitoring neoadjuvant chemotherapy. Breast Cancer Res (2005) 2.68
The mammalian gene function resource: the International Knockout Mouse Consortium. Mamm Genome (2012) 2.65
Community-based interventions to promote blood pressure control in a developing country: a cluster randomized trial. Ann Intern Med (2009) 2.64
Cancer survival in Kentucky and health insurance coverage. Arch Intern Med (2003) 2.61
Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ (2014) 2.60
NORDCAN--a Nordic tool for cancer information, planning, quality control and research. Acta Oncol (2010) 2.48
Cost-effectiveness of community-based strategies for blood pressure control in a low-income developing country: findings from a cluster-randomized, factorial-controlled trial. Circulation (2011) 2.44
[Cancer survival before and after initiating the Danish Cancer Control plan]. Ugeskr Laeger (2008) 2.41
Changes in mental health of UK hospital consultants since the mid-1990s. Lancet (2005) 2.34
Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma. Clin Cancer Res (2008) 2.23
Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007. Thorax (2013) 2.19
Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol (2011) 2.19
Long-term trends in incidence, survival and mortality of primary penile cancer in England. Cancer Causes Control (2013) 2.18
International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer (2008) 2.13
Monitoring neoadjuvant chemotherapy in breast cancer using quantitative diffuse optical spectroscopy: a case study. J Biomed Opt (2004) 2.12
"We are all in this together": integrated health service plans in Ontario. Healthc Q (2007) 2.08
Dual RMCE for efficient re-engineering of mouse mutant alleles. Nat Methods (2010) 2.05
Diffuse optical monitoring of blood flow and oxygenation in human breast cancer during early stages of neoadjuvant chemotherapy. J Biomed Opt (2007) 2.01
Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol Oncol (2005) 1.98
Familial risks in nervous-system tumours: a histology-specific analysis from Sweden and Norway. Lancet Oncol (2009) 1.95
Use of albumin creatinine ratio and urine albumin concentration as a screening test for albuminuria in an Indo-Asian population. Nephrol Dial Transplant (2007) 1.91
Income inequality, individual income, and mortality in Danish adults: analysis of pooled data from two cohort studies. BMJ (2002) 1.89
Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol (2007) 1.89
Continuing rapid increase in esophageal adenocarcinoma in England and Wales. Am J Gastroenterol (2008) 1.85
Seasonal variation in hospital discharge diagnosis of atrial fibrillation: a population-based study. Epidemiology (2002) 1.85
Long-term use of statins and risk of colorectal cancer: a population-based study. Am J Gastroenterol (2009) 1.83
Prevalence and factors associated with intestinal parasitic infection among children in an urban slum of Karachi. PLoS One (2008) 1.80
A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers. J Proteome Res (2007) 1.80
Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet Oncol (2006) 1.79
Advanced breast cancer patients' perceptions of decision making for palliative chemotherapy. J Clin Oncol (2006) 1.67
Geographical variation in life expectancy at birth in England and Wales is largely explained by deprivation. J Epidemiol Community Health (2005) 1.66
Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971. Am J Gastroenterol (2010) 1.65
Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary. Gynecol Oncol (2010) 1.64
Self-assembled virus-membrane complexes. Nat Mater (2004) 1.63
Second primary cancers in patients with nasopharyngeal carcinoma: a pooled analysis of 13 cancer registries. Cancer Causes Control (2007) 1.61
The fallopian tube: primary site of most pelvic high-grade serous carcinomas. Int J Gynecol Cancer (2009) 1.60
Childhood cancer survival in Europe and the United States. Cancer (2002) 1.59
X-inactivation reveals epigenetic anomalies in most hESC but identifies sublines that initiate as expected. J Cell Physiol (2008) 1.59
Peritoneal lavage cytology: an assessment of its value during prophylactic oophorectomy. Gynecol Oncol (2002) 1.59
Social inequality in incidence of and survival from cancer in a population-based study in Denmark, 1994-2003: Summary of findings. Eur J Cancer (2008) 1.57
Waterpipe use predicts progression to regular cigarette smoking among Danish youth. Subst Use Misuse (2010) 1.55
Second primary cancers in thyroid cancer patients: a multinational record linkage study. J Clin Endocrinol Metab (2006) 1.54
Comparability of stage data in cancer registries in six countries: lessons from the International Cancer Benchmarking Partnership. Int J Cancer (2012) 1.54
Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers. Int J Cancer (2006) 1.53